Plain-English translation of NCT06826768 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing a combination of two medications: (a bispecific antibody designed to attack prostate cancer cells) and (a medication that helps your immune system fight cancer). Researchers want to find the right dose of these medications when given together, and to understand how safe and effective this combination might be for men with advanced prostate cancer.
Men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments have limited options. This trial is exploring whether combining these two immunotherapy approaches—one that targets prostate cancer cells directly and one that boosts the immune system—could offer a new treatment option.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the two medications intravenously (into your vein). The trial starts with a lead-in phase where you receive three weekly doses of the first medication, then transitions to both medications given together every three weeks. You will need to attend regular clinic visits for blood tests, imaging scans, and monitoring of side effects. The study also involves providing tumor tissue samples and allowing researchers to study your immune response before and after treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
M.D. Anderson Cancer Center
Collaborators
Regeneron Pharmaceuticals
Enrollment target
~60 participants
Started
July 2025
Primary completion
May 2027
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Bilal Siddiqui, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.